Serina Therapeutics Inc reports a Return on Equity (ROE) of -120.64%.

What is SER's dividend yield?

Serina Therapeutics Inc offers a dividend yield of 0.00%.

What is SER's Quality Score?

Our AI rates SER's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy SER?

Our AI Timing Score for SER is 6 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does SER belong to?

Serina Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange

Serina Therapeutics Inc (SER) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

SER AI Analysis Summary

Our AI summary for SER: Serina Therapeutics Inc (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at ROE of -120.64%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 6/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

SER

Serina Therapeutics Inc

US:NYSE MKT STOCK Healthcare >> Biotechnology News 90

USD 2.06

0.06 (3.00%) Day Change

Watchlist Portfolio Compare Chart

0.17

D/E

-120.6%

ROE

-77.9%

ROA

0.00%

Div Yield

SERINA THERAPEUTICS INC
TYPE: STOCK
MARKET: NYSE MKT

Compare Watchlist Myport

USD 2.06 Price 0.06 (3.00%) Day Change	NEWS SCORE: 90

SER, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	90
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.06
PBV / Sector	1.70 / 44,219.29
Earning Per Share	-1.46

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	0.07 M GREAT
Average 1W Daily Value	0.03 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-16,359.23 / 98.22
NPM Average (%) / Sector	-10,275.71 / -1,697.63
NPM Change Average (%) / Sector	-3,037.80 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-77.90 / 185,260.96
ROA Average (%) / Sector	-108.71 / 36,684.70
ROA Change Average (%) / Sector	-139.56 / 422,221.66
ROE (%) / Sector	-120.64 / 243,762.23
ROE Average (%) / Sector	10,025.66 / 48,758.47
ROE Change Average (%) / Sector	-979.02 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:02:08
Symbol	SER
Name	SERINA THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NYSE MKT
Listed Shares	15.00 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	30.00 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 601 Genome Way, Huntsville, AL, United States, 35806

Phone: 256 327 9630

Website: https://serinatherapeutics.com

Sector: Healthcare >> Biotechnology

Description: Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.